Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives

News

 22nd October 2009
PolyTherics

PolyTherics Announces New Senior Management Appointments

Strengthening of team prepares company for future product development strategy

PolyTherics Limited (“PolyTherics”), the biopharmaceuticals company dedicated to precision engineering of proteins to improve their pharmacokinetic properties, today announced two key appointments to its senior management team. The announcement comes as PolyTherics is poised to expand its capabilities for developing PEGylated biopharmaceuticals for therapeutic application.

Dr Sally Waterman, previously Director of Research & Development at Protherics (now part of BTG), joins PolyTherics as Chief Operating Officer. Sally was most recently responsible for global drug development and a polymer research group in Salt Lake City which undertook formulation feasibility studies for third parties and supported proprietary programmes. Prior to Protherics Sally held a similar position with KS Biomedix (acquired by Xenova) and before that managed the non-clinical development group at Vernalis.

Dr Jeff Edwards has also joined PolyTherics as Director of Development. Jeff was previously responsible for development at Thiakis, an Imperial College spin-out company focused on the discovery and development of drugs for obesity and acquired by Wyeth in December 2008. Jeff had previously held positions as Director of Alliance Management and Head of Exploratory Development at Ipsen where his responsibilities included therapeutic peptide development.

PolyTherics is creating a successful business by using its platform of targeted PEGylation technologies to optimise therapeutic products for its partners and for in-house programmes for later stage outlicensing. These two key appointments therefore underpin the management foundations of the company as it prepares to deliver on this strategy.

Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “I am delighted to welcome both Sally and Jeff to PolyTherics at a very exciting time in the evolution of the company. Attracting individuals of their calibre and experience as we progress into proprietary product development is central to delivering on our stated strategy”.

For further information, please contact:

Keith Powell +44 (0) 207 691 4928 CEO

Mike Wort / Anna Dunphy +44 (0) 207 861 3838 De Facto Communications


 

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |